Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

INHIBITOR Therapeutics

INHIBITOR Therapeutics
1992 FOUNDED
PUBLIC STATUS
1-10 EMPLOYEES
INTI STOCK SYMBOL
$0.04 SHARE PRICE (As of Monday Closing)
Description

Inhibitor Therapeutics Inc, formerly HedgePath Pharmaceuticals Inc is a pharmaceutical development company focused on developing and commercializing therapies for patients with cancer and non-cancerous proliferation disorders. The company's main focus is to advance its lead product, SUBA-Itraconazole a patented, oral formulation of the currently marketed, well-understood, anti-fungal drug, Itraconazole, for prostate and lung cancer.

Formerly Known As
Hedgepath Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Discovery Tools (Healthcare)
Stock Exchange
PINX
Primary Office
  • 324 South Hyde Park Avenue
  • Suite 350
  • Tampa, FL 33606
  • United States

+1 (813) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore INHIBITOR Therapeutics’s full profile, request a free trial.

INHIBITOR Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$14.1M $0.05 -$0.01 18.4K 370M

INHIBITOR Therapeutics Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 24,237 24,718 91,882 134,277
Revenue 0 0 0 0
EBITDA (3,440) (4,564) (5,119) (7,022)
Net Income (3,424) (4,550) (5,101) (7,000)
Total Assets 1,484 1,233 768 7,338
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

INHIBITOR Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore INHIBITOR Therapeutics‘s full profile, request access.

Request full access to PitchBook

INHIBITOR Therapeutics Competitors (33)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ra Pharmaceuticals Formerly VC-backed Cambridge, MA 00 00000 000000&0 00000
0000000 0000000000 Formerly VC-backed Dallas, TX 00 00000 000000&0 00000
00000 000000000000 Corporate Backed or Acquired Carlsbad, CA 000 0000 00000000000 0000
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
0000000 0000000000 Corporation San Diego, CA 00 00000 000000000 00000
To view this company’s complete list of competitors, request access »

INHIBITOR Therapeutics Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore INHIBITOR Therapeutics‘s full profile, request access.

Request full access to PitchBook

INHIBITOR Therapeutics Executive Team (3)

Name Title Board
Seat
Contact
Info
Nicholas Virca President and Chief Executive Officer
Garrison Hasara Chief Financial Officer and Treasurer
James McNulty Secretary, Compliance Officer and Treasurer

INHIBITOR Therapeutics Board Members (1)

Name Representing Role Since Contact
Info
000000 00000 00. INHIBITOR Therapeutics Board Member 000 0000